0001209191-23-022398.txt : 20230403 0001209191-23-022398.hdr.sgml : 20230403 20230403192441 ACCESSION NUMBER: 0001209191-23-022398 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230330 FILED AS OF DATE: 20230403 DATE AS OF CHANGE: 20230403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZANTE GREG CENTRAL INDEX KEY: 0001264949 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 23794555 MAIL ADDRESS: STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100 STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD, CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-30 0 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 0 Common Stock, par value $0.00001 per share 2023-03-30 4 M 0 32000 8.52 A 217057 D Common Stock, par value $0.00001 per share 2023-03-30 4 M 0 42000 7.69 A 259057 D Common Stock, par value $0.00001 per share 2023-03-30 4 M 0 12250 4.65 A 271307 D Common Stock, par value $0.00001 per share 2023-03-30 4 M 0 7500 4.12 A 278807 D Common Stock, par value $0.00001 per share 2023-03-30 4 S 0 131029 17.0025 D 147778 D Common Stock, par value $0.00001 per share 2023-04-03 4 M 0 30911 7.77 A 178689 D Common Stock, par value $0.00001 per share 2023-04-03 4 S 0 30911 18.00 D 147778 D Common Stock, par value $0.00001 per share 2023-04-03 4 A 0 56667 0.00 A 204445 D Common Stock, par value $0.00001 per share 2023-04-03 4 F 0 55166 17.57 D 149279 D Stock Option (right to buy) 8.52 2023-03-30 4 M 0 32000 0.00 D 2020-01-15 2029-01-15 Common Stock 32000 0 D Stock Option (right to buy) 7.69 2023-03-30 4 M 0 42000 0.00 D 2020-07-31 2029-07-31 Common Stock 42000 0 D Stock Option (right to buy) 4.65 2023-03-30 4 M 0 12250 0.00 D 2019-01-19 2028-01-19 Common Stock 12250 0 D Stock Option (right to buy) 4.12 2023-03-30 4 M 0 7500 0.00 D 2018-04-30 2028-04-30 Common Stock 7500 0 D Stock Option (right to buy) 7.77 2023-04-03 4 M 0 30911 0.00 D 2021-01-03 2030-01-03 Common Stock 30911 0 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. 25% of the shares subject to the option vested on each one year anniversary of the grant date. One-third of the shares subject to the option vested on each one year anniversary of the grant date. 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. /s/ Michael Morneau as Attorney-in-Fact 2023-04-03